Insights

Strategic Acquisition MINAKEM expanded its footprint with the Delmar acquisition in Montreal in July 2023, signaling growth potential and a broader North American customer base for high potency APIs and complex intermediates.

Sustainability Recognition EcoVadis Gold Medal achieved in May 2023 highlights strong sustainability practices, which can be leveraged to win business with sustainability-conscious pharma clients and aligned supply chain partnerships.

Global Ultra-Competence Operating across four sites in France, Belgium, Canada, and access to Minafin Group resources positions MINAKEM for regional supply security, regulatory agility, and multi-site manufacturing capabilities for complex projects.

High Potent & Specialties Specialization in high potency APIs, multi-step synthesis, chiral and pressure chemistry, and ADC linker development presents clear upsell avenues with innovators and generic players seeking advanced manufacturing and development services.

Full Development Partner End-to-end offering from API development to commercial manufacturing, QA, regulatory, and SHE support creates opportunities to win integrated programs with pharmaceutical companies seeking a single partner for development and manufacture.

MINAKEM Tech Stack

MINAKEM uses 8 technology products and services including Agilent, Microsoft Outlook, Punycode, and more. Explore MINAKEM's tech stack below.

  • Agilent
    Data Management
  • Microsoft Outlook
    Email
  • Punycode
    Font Scripts
  • OpenAI
    Generative Ai
  • JSON-LD
    Javascript Frameworks
  • Really Simple Discovery
    Miscellaneous
  • VMware vSphere
    Virtualisation Software
  • Royal-Slider
    Web Tools And Plugins

MINAKEM's Email Address Formats

MINAKEM uses at least 1 format(s):
MINAKEM Email FormatsExamplePercentage
First.Last@minakem.comJohn.Doe@minakem.com
92%
FLast@minakem.comJDoe@minakem.com
5%
First@minakem.comJohn@minakem.com
2%
FirstLast@minakem.comJohnDoe@minakem.com
1%

Frequently Asked Questions

What is MINAKEM's phone number?

Minus sign iconPlus sign icon
You can contact MINAKEM's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is MINAKEM's official website and social media links?

Minus sign iconPlus sign icon
MINAKEM's official website is minakem.com and has social profiles on LinkedInCrunchbase.

How much revenue does MINAKEM generate?

Minus sign iconPlus sign icon
As of July 2026, MINAKEM's annual revenue is estimated to be $1M - $10M.

What is MINAKEM's SIC code NAICS code?

Minus sign iconPlus sign icon
MINAKEM's SIC code is 2834 - Pharmaceutical Preparations NAICS code is 325 - Chemical Manufacturing.

How many employees does MINAKEM have currently?

Minus sign iconPlus sign icon
As of July 2026, MINAKEM has approximately 360 employees across 3 continents, including EuropeNorth AmericaAsia. Key team members include Ceo: O. U.Chief Accounting Officer: I. C.Head Of Analytical Development: M. D.. Explore MINAKEM's employee directory with LeadIQ.

What industry does MINAKEM belong to?

Minus sign iconPlus sign icon
MINAKEM operates in the Chemical Manufacturing industry.

What technology does MINAKEM use?

Minus sign iconPlus sign icon
MINAKEM's tech stack includes AgilentMicrosoft OutlookPunycodeOpenAIJSON-LDReally Simple DiscoveryVMware vSphereRoyal-Slider.

What is MINAKEM's email format?

Minus sign iconPlus sign icon
MINAKEM's email format typically follows the pattern of First.Last@minakem.com. Find more MINAKEM email formats with LeadIQ.

How much funding has MINAKEM raised to date?

Minus sign iconPlus sign icon
As of July 2026, MINAKEM has raised $18M in funding. The last funding round occurred on Mar 12, 2018 for $18M.

When was MINAKEM founded?

Minus sign iconPlus sign icon
MINAKEM was founded in 2004.
MINAKEM logo

MINAKEM

Chemical ManufacturingHauts-de-France, France201-500 Employees

MINAKEM is a fully integrated development partner and contract manufacturer serving pharmaceutical companies, providing active pharmaceutical ingredients for innovators, generics, and highly potent compounds. It offers custom development and manufacturing, and produces key intermediates and building blocks, all supported by R&D centers and analytical services that include solid-form analysis and quality-by-design laboratories. The company is technology-driven and capable of handling complex multi-step syntheses across various chemistries, with operations across multiple sites in Europe and North America, including Dunkirk and Beuvry-la-Forêt in France, Louvain-la-Neuve in Belgium, and Montréal in Canada, each approved by US FDA and local health authorities; MINAKEM is part of the Minafin Group. 

Its client base comprises pharmaceutical developers and manufacturers seeking reliable API supply, development support, and scale-up capabilities, with a focus on flexibility and responsiveness across its network to strengthen supply chains. In July 2023, MINAKEM expanded its footprint with the acquisition of Delmar in Montréal, Canada, reinforcing its North American presence.

Section iconCompany Overview

Phone number
SIC Code
2834 - Pharmaceutical Preparations
NAICS Code
325 - Chemical Manufacturing
Founded
2004
Employees
201-500

Section iconFunding & Financials

  • $18M

    MINAKEM has raised a total of $18M of funding over 1 rounds. Their latest funding round was raised on Mar 12, 2018 in the amount of $18Mas a series_unknown.

  • $1M - $10M

    MINAKEM's revenue is estimated to be in the range of $1M - $10M

Section iconFunding & Financials

  • $18M

    MINAKEM has raised a total of $18M of funding over 1 rounds. Their latest funding round was raised on Mar 12, 2018 in the amount of $18Mas a series_unknown.

  • $1M - $10M

    MINAKEM's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.